About Aficamten API
Therapeutic CategoryCardiology
CAS Number
2364554‑48‑1
API Technology
Small‑molecule synthetic API
Dose Form
Tablets
Dr Reddy's Development Status
Under Development
Mechanism of action
Aficamten binds directly to the catalytic (motor) domain of cardiac myosin (β‑myosin heavy chain).
It stabilizes myosin in a weak actin‑binding state, preventing transition into the force‑generating state.
This reduces the number of active myosin heads, resulting in:
Decreased myocardial hypercontractility
Reduced left ventricular outflow tract (LVOT) obstruction
Overall effect: improved diastolic function and symptom relief in obstructive hypertrophic cardiomyopathy (oHCM).
Indication
Treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to:
Improve functional capacity
Reduce symptoms such as dyspnea and exercise intolerance
Related APIs
Acoramidis
Cardiology
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
Disclaimer
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.